Kent Lake Capital’s Fulgent Genetics FLGT Stock Holding History

Kent Lake Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,000	Closed	-$3.7M	–	57
2023 Q2	$3.7M	Buy	+100,000	New	+$3.49M	1.7%	21

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kent Lake Capital's FLGT Position: Q3 2023 in Review

Kent Lake Capital sold out of Fulgent Genetics (FLGT) in Q3 2023, closing a stake of 100,000 shares — an estimated $3.7M sold.

Kent Lake Capital first reported a position in FLGT in Q2 2023 and held it in 1 quarter. The position peaked at $3.7M in Q2 2023. 201 funds tracked by Wall St. Rank hold FLGT as of Q3 2023.

Kent Lake Capital reported no remaining Fulgent Genetics position as of Q3 2023 after selling out during the quarter.
Kent Lake Capital sold 100,000 Fulgent Genetics shares in Q3 2023, an estimated $3.7M.
Kent Lake Capital first reported a position in Fulgent Genetics in Q2 2023 and held it in 1 quarter.
Kent Lake Capital's Fulgent Genetics position peaked at $3.7M in Q2 2023.
201 funds tracked by Wall St. Rank held Fulgent Genetics as of Q3 2023.

Based on Kent Lake Capital's 13F filing for Q3 2023, filed 14 Nov 2023.